Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor

Chu, Seung Y.; Yeter, Karen; Kotha, Roshan; Pong, Erik; Miranda, Yvonne; Phung, Sheryl; Chen, Hsing; Lee, Sung-Hyung; Leung, Irene; Bonzon, Christine; Desjarlais, John R.; Stohl, William; Szymkowski, David E.

doi:10.1002/art.38334

Cited by 53 publications

(23 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 This molecule has demonstrated efficacy in suppressing B cell activation and proliferation as well as disease activity in rheumatoid arthritis. 59 We recently completed enrollment on an open-label, single-arm study on its efficacy in IgG4-RD. 60 Preliminary analyses of this approach are promising and have been reported.…”

Section: From Bench To Bedsidementioning

confidence: 99%

Emerging Treatment Models in Rheumatology: IgG4‐Related Disease: Insights Into Human Immunology and Targeted Therapies

Perugino

Mattoo

Mahajan

et al. 2017

Arthritis & Rheumatology

View full text Add to dashboard Cite

Section: From Bench To Bedsidementioning

confidence: 99%

Emerging Treatment Models in Rheumatology: IgG4‐Related Disease: Insights Into Human Immunology and Targeted Therapies

Perugino

Mattoo

Mahajan

et al. 2017

Arthritis & Rheumatology

View full text Add to dashboard Cite

“…Conversely antiinflammatory therapeutics include the harnessing of the inhibitory FccRIIb by antibodies targeting activating type immunoreceptors but whose Fc portions have been engineered to selectively or preferentially engage FccRIIb. This results in a stable co-clustering of an activating type immunoreceptor with the inhibitory FccRIIb (Chu et al 2012(Chu et al , 2013Horton et al 2011).…”

Section: Introductionmentioning

confidence: 97%

The FcγR of Humans and Non-human Primates and Their Interaction with IgG: Implications for Induction of Inflammation, Resistance to Infection and the Use of Therapeutic Monoclonal Antibodies

Hogarth

Anania

Wines

2014

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Considerable effort has focused on the roles of the individual members of the FcγR receptor (FcγR) family in inflammatory diseases and humoral immunity. Recent work has revealed major roles in infection and in particular HIV pathogenesis and immunity. In addition, FcγR functions underpin the action of many of the successful therapeutic monoclonal antibodies. This emphasises the need for a greater understanding of FcγR function in humans and in the NHP which provides a key model for human immunity and preclinical testing of antibodies. We discuss recent key aspects of the human FcγR receptor biology and structure to define differences and similarities in activity between the human and macaque Fc receptors. These differences and similarities nuance the interpretation of infection and vaccine studies in the macaque. Indeed passive IgG antibody protection in lentivirus infection models in the macaque provided early evidence for the role of Fc receptors in anti-HIV immunity that have subsequently gained support from human vaccine trials. None-the-less the diverse functions and cellular contexts of FcγR receptor expression ensure there is much still to understand of the protective and deleterious effects of FcγRs in HIV infection. Careful comparative studies of human and non-human primate FcγRs will facilitate our appreciation of what attributes of HIV specific IgG antibodies, either acquired naturally or via vaccination, are most important for protection.

show abstract

“…Another surface antigen CD19 has also been suggested as a promising marker for targeting B lymphocyte in RA [155] , which can also serve as another CAR-T cell therapeutic target. The humoral responses of B lymphocytes isolated from RA patients are repressed by the administration of the monoclonal anti-19 antibody XmAb5871 which facilitate the engagement of CD19, B cell antigen receptor, and Fcγ receptor IIb inhibitory receptor [156]. When compared with the passive administration of monoclonal antibody, CAR-T cells are benefited from its tissue biodistribution property because of their extravasate capacity [157], active responses to chemokine signaling [158], and the secretory ability of proteolytic enzymes [159].…”

Section: Innovative Therapeutic Strategies For Refractory Ra With CLImentioning

confidence: 99%

Immunotherapeutic Approaches of Rheumatoid Arthritis and the Implication on Novel Interventions for Refractoriness

Mok¹,

Law²,

Kam-WaiWong³

et al. 2018

Immunoregulatory Aspects of Immunotherapy

View full text Add to dashboard Cite

Rheumatoid arthritis is an autoimmune disorder involving the chronic inflammation of affected joints which lead to the distortion and eventually destruction of the articular tissues. Clinically, many therapeutic methods are being used for RA treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs), steroid, and disease-modifying antirheumatic drugs (DMARDs) are the three main categories of intervention approaches. Among which DMARDs, targeting mainly the release of pro-inflammatory cytokines, demonstrated high efficacy because of its direct drug action that alter the underlying disease mechanisms rather than simply to mediate symptoms relieve. However, the use of DMARDs also accompanying some unwanted adverse side effects, in particular, the development of refractoriness, which hampers the successful rate of treatment. In this chapter, the conventional RA drugs will be reviewed, focusing on the currently used and latest development of DMARDs. Novel methods that could improve RA pathogenesis will also be introduced. Because of the critical role of refractory RA, the progress of the disease to develop resistance to standard drug treatment will also be described. Finally, innovative RA therapeutic methods inspired by researches concerning the pathogenesis and contemporary treatments of RA will be discussed.

show abstract

Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor

Abstract: Objective. Engagement of Fc␥ receptor

Cited by 53 publications

References 48 publications

Emerging Treatment Models in Rheumatology: IgG4‐Related Disease: Insights Into Human Immunology and Targeted Therapies

Emerging Treatment Models in Rheumatology: IgG4‐Related Disease: Insights Into Human Immunology and Targeted Therapies

The FcγR of Humans and Non-human Primates and Their Interaction with IgG: Implications for Induction of Inflammation, Resistance to Infection and the Use of Therapeutic Monoclonal Antibodies

Immunotherapeutic Approaches of Rheumatoid Arthritis and the Implication on Novel Interventions for Refractoriness

Contact Info

Product

Resources

About